Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma

Strahlentherapie und Onkologie

Volumn 183, Issue 5, 2007, Pages 256-264

  Schütze, Christina ^a   Dörfler, Annegret ^a   Eicheler, Wolfgang ^a   Zips, Daniel ^a   Hering, Sandra ^a   Solca, Flavio ^b   Baumann, Michael ^a   Krause, Mechthild ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

BIBW 2669; BIBW 2992; EGFR HER2 TK inhibition; Human tumor xenografts; Irradiation; Squamous cell carcinoma; Tumor growth delay

Indexed keywords

BIBW 2669; BIBW 2992; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRRADIATION; MALE; MOUSE; NONHUMAN; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 34248144881     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1696-z     Document Type: Article

References (48)

1. Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 2005;6:259-74.
2. Ang K, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
3. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
4. Baumann M, Dubois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990;123:325-30.
5. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-66.
6. Baumann M, Krause M, Zips D, et al. Selective inhibition of the epidermal growth factor tyrosine kinase by BIBX1382BS improves growth delay but not local control after fractionated irradiation in human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003;79:547-59.
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
8. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:1125-35.
9. Burdak-Rothkamm S, Rube CE, Nguyen TP, et al. Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa® ). Strahlenther Onkol 2005;181:197-204.
10. Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
11. Eicheler W, Dörfler A, Krause M, et al. Expression levels of EGFR, ErbB2, and ErbB3 compared to cellular radiation sensitivity and the response to EGFR inhibitors C225 and BIBX1382BS in human tumour cell lines in vitro. Radiother Oncol 2006;81:Suppl 1:S30-1.abstract.
12. Eicheler W, Zips D, Dorfler A, et al. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem 2002;50:197-204.
13. Erlichman C, Hidalgo M, Boni JP, et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006;24:2252-60.
14. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
15. Hoekstra R, Dumez H, Eskens FA, et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2005;11:6908-15.
16. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-69.
17. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
18. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
19. Krause M, Hessel F, Zips D, et al. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radiother Oncol 2004;72:95-101.
20. Krause M, Prager J, Wohlfarth J, et al. Ultrafractionation does not improve the results of radiotherapy in radioresistant murine DDL1 lymphoma. Strahlenther Onkol 2005;181:540-4.
21. Krause M, Schutze C, Petersen C, et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 2005;74:109-15.
22. Krause M, Zips D, Thames HD, et al. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 2006;80:112-22.
23. Krempien R, Muenter MW, Huber PE, et al. Randomized phase II study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283]. BMC Cancer 2005;5:131.
24. Kuhnt T, Janich M, Gotz U, et al. [Presentation of a 3D conformal radiotherapy technique for head-and-neck tumors resulting in substantial protection of the parotid glands.] Strahlenther Onkol 2006;182:325-30.
25. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004;58:903-13.
26. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
27. Nasu S, Ang KK, Fan Z, et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001;51:474-7.
28. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
29. Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972;29:117-21.
30. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004;90:2250-5.
31. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996;7:133-41.
32. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
33. Schütze C, Krause M. K-ras-Mutationen in menschlichen Tumorzelllinien führen durch EGFR-abhängige Aktivierung der PI3K-AKT-Signalkaskade zur Strahlenresistenz. Literatur kommentiert. Strahlenther Onkol 2006;182:252-3.
34. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
35. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
36. Solca F, Baum A, Guth B, et al. BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy. Presented at the AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" Philadelphia, Nov. 14-18, 2005, Abstract A244.
37. Spector NL, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
38. Steel GG. Growth kinetics of tumours: cell population kinetics in relation to the growth and treatment of cancer. Oxford: Clarendon Press, 1977.
39. Stopfer P, Schaefer H, Amelsberg A, et al. Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2005;11:Suppl:9075S.
40. Suit HD, Zietman A, Tomkinson K, et al. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys 1990;18:365-73.
41. Threadgill DW, Dlugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995;269:230-4.
42. Toulany M, Dittmann K, Baumann M, et al. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol 2005;74:117-29.
43. Toulany M, Dittmann K, Kruger M, et al. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 2005;76:143-50.
44. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
45. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
46. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
47. Zhou Y, Li S, Hu YP, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 2006;66:404-11.
48. Zietman AL, Suit HD, Ramsay JR, et al. Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr/Sed nude mice. Cancer Res 1988;48:6510-6.